Clinical trials: Adalimumab
Crohn's Disease
Switching From Adalimumab to Infliximab
Switching to Adalimumab has proven to be efficacious in Crohn's disease (CD) patients with intolerance or loss of response to Infliximab.
- Trial name
- ADA-IFX (NCT01338740)
- Testing
- Adalimumab and Infliximab
- Where
- 16 sites in Belgium
- Volunteers
- 21 people
- Sponsor
- University Hospital, Ghent
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT03789292
- Testing
- CT-P17 SC, Humira SC
- Where
- Bulgaria
- Volunteers
- 648 people
- Sponsor
- Celltrion
Hidradenitis Suppurativa
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
The primary objective of this randomized controlled clinical trial in a real life setting is to evaluate the cost-utility of limumab monotherapy compared with the combination of adalimumab and a maximum of three surgeries after…
- Trial name
- HS-COST (NCT03221621)
- Testing
- Wide Excision, Adalimumab Injection
- Where
- Netherlands
- Volunteers
- 128 people
- Sponsor
- Erasmus Medical Center
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with…
- Trial name
- EPIC (NCT01401452)
- Volunteers
- 246 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity
Hulio is a monoclonal antibody currently approved as a biosimilar to European Union approved and United States (US)-Licensed Humira.
- Trial name
- NCT05637515
- Testing
- Humira 40 MG in Prefilled Syringe, Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe
- Where
- 36 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 374 people
- Sponsor
- Biocon Biologics Inc.
Ankylosing Spondylitis
Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis
Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of ankylosing spondylitis patient safety and efficacy.
- Trial name
- NCT02456363
- Testing
- TNF alpha, NSAIDs and sulfasalazine
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chung Shan Medical University
Pediatric Crohn's Disease
Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"
This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea.
- Trial name
- NCT02578238
- Volunteers
- 143 people
- Sponsor
- AbbVie
Pain, Injection Site
Adalimumab Microneedles in Healthy Volunteers
Adalimumab (Humira, AbbVie) is a highly effective treatment for a variety of auto-immune/auto-inflammatory diseases including juvenile idiopathic arthritis (JIA).
- Trial name
- NCT03607903
- Testing
- Adalimumab ID, Adalimumab SC, Saline ID
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre for Human Drug Research, Netherlands
Ulcerative Colitis
Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
To evaluate the real-life effect after 1 year of adalimumab treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
- Trial name
- UCanADA (NCT02506179)
- Where
- 23 sites in Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
PHASE: IV DESCRIPTIVE: Randomized, interventional, open label multicenter trial POPULATION: Moderate to severe ulcerative colitis STUDY TREATMENTS: Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by…
- Trial name
- CONTROL (NCT04183608)
- Testing
- Adalimumab, Calprotectin, e-Monitoring
- Where
- 24 sites in France
- Volunteers
- 238 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Behcet Syndrome, Intestinal Type
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS).
- Trial name
- NCT06849908
- Testing
- Baricitinib, Adalimumab
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Peking Union Medical College Hospital
Rheumatoid Arthritis
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis.
- Trial name
- NCT00853385
- Testing
- CP 690,550, CP-690,550, Biologic TNFi
- Where
- 125 sites in United States, Australia and 19 more
- Volunteers
- 717 people
- Sponsor
- Pfizer
AS
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory…
- Trial name
- NCT02893254
- Testing
- IBI303, Adalimumab
- Volunteers
- 438 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Spondyloarthritis
Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or infliximab), and in stable low disease activity for at least 6 months, will be randomized into 2 groups: either keeping on their usual…
- Trial name
- SPACING (NCT01610947)
- Testing
- Adalimumab, Etanercept, Golimumab or infliximab
- Where
- France
- Volunteers
- 398 people
- Sponsor
- University Hospital, Montpellier
Psoriasi
Effect of Adalimumab Therapy on Psoriasis Patient
to evaluate the impact of adalimumab therapy on quality of life in patient with severe psoriasis.
- Trial name
- NCT05889338
- Testing
- adalimumab and methotrexate
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Sohag University
Rheumatoid Arthritis
Rheumatoid Arthritis Satisfaction Outcome Research
RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2…
- Trial name
- NCT03703817
- Where
- 23 sites in South Korea
- Volunteers
- 421 people
- Sponsor
- Pfizer
Moderate to Severe Ulcerative Colitis
Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
The objectives of this study are to explore the fecal calprotectin (fC) levels of UC patients under adalimumab therapy and the correlation with their general wellbeing (Quality of Life [QoL]), workability, and disease activity.
- Trial name
- AdaProQuo (NCT02092389)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Crohn's Disease
Remission in Subjects With Crohn's Disease, 1 Year Phase
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of…
- Trial name
- CLASSICII (NCT00055497)
- Testing
- DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Where
- 43 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Crohn´s Disease
Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
The present study objective is evaluate Adalimumab efficacy versus Azathioprine efficacy on prevention of endoscopic recurrence (Rutgeerts Index= 2b, 3 or 4) in Crohn´s Disease patients after 52 weeks of treatment.
- Trial name
- APPRECIA (NCT01564823)
- Testing
- Metronidazole, Azathioprine, Adalimumab
- Where
- 22 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Plaque Psoriasis
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
- Trial name
- PsOsim (NCT02489227)
- Testing
- CHS-1420, Adalimumab
- Where
- 99 sites in United States, Bulgaria and 14 more
- Volunteers
- 545 people
- Sponsor
- Coherus Oncology, Inc.